Recurrent respiratory papillomatosis (RRP) is a disease characterized by benign papillomatous lesions of the upper airway that often cause debilitating dysphonia and may result in airway obstruction. Because of its recurrent nature, multiple surgical excisions are required to manage RRP, resulting in patient morbidity and high health care use.
1,2 Intralesional injections of the antiviral medication cidofovir have been used in an attempt to decrease the frequency of excisions and reduce the burden of disease for the patient
3,4; however, there have been concerns that cidofovir may produce adverse effects, including increased risk of malignant transformation.
5 Although several studies have found no increased risk of cancer in patients with RRP who are treated with cidofovir,
6-11 the safety profile of intralesional cidofovir injection in patients with RRP is not fully understood. Understanding the safety of intralesional cidofovir is essential for otolaryngologists treating patients with RRP with a high burden of disease who may be seeking adjuvant therapies. This study aims to provide further data on the safety of intralesional adjuvant cidofovir to inform physicians in their decision to offer this treatment to patients.